Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer

Fairooz F. Kabbinavar, Joel F. Wallace, Eric Holmgren, Jing Yi, David Cella, Kathleen J Yost, Herbert I. Hurwitz

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose. To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies. Patients and Methods. Prespecified HRQoL endpoints in the phase II (Study 2192) and phase III (Study 2107) studies were time to deterioration in HRQoL, measured by the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Colorectal Cancer Subscale (CCS), Trial Outcome Index (TOI-C), and FACT-C total score. Time to deterioration in HRQoL was evaluated for patients with baseline and postbaseline assessments, using the stratified log-rank test. Results. In the pivotal phase III trial, HRQoL baseline and postbaseline CCS scores were available for 127 patients receiving irinotecan, 5-FU, and leucovorin (LV) (IFL) and 122 patients receiving IFL plus BV. The time to deterioration in HRQoL did not differ significantly between treatment groups as measured by the CCS, TOI-C, or FACT-C total score. In the phase II study, baseline and postbaseline CCS scores were available for 77 and 89 patients receiving 5-FU and LV and 5-FU and LV plus BV, respectively. In that study, the time to deterioration in HRQoL was similar between groups as measured by the CCS and TOI-C scores, but was significantly longer in the 5-FU and LV plus BV arm than in the 5-FU and LV plus placebo arm for the FACT-C total score. Conclusions. When added to 5-FU chemotherapy, BV significantly prolonged overall survival and progression-free survival without compromising HRQoL.

Original languageEnglish (US)
Pages (from-to)1021-1029
Number of pages9
JournalOncologist
Volume13
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
Quality of Life
Placebos
Bevacizumab
Therapeutics
Drug Therapy

Keywords

  • Angiogenesis inhibitors
  • Bevacizumab
  • Colorectal cancer
  • Fluorouracil
  • Monoclonal antibodies
  • Quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. / Kabbinavar, Fairooz F.; Wallace, Joel F.; Holmgren, Eric; Yi, Jing; Cella, David; Yost, Kathleen J; Hurwitz, Herbert I.

In: Oncologist, Vol. 13, No. 9, 09.2008, p. 1021-1029.

Research output: Contribution to journalArticle

Kabbinavar, Fairooz F. ; Wallace, Joel F. ; Holmgren, Eric ; Yi, Jing ; Cella, David ; Yost, Kathleen J ; Hurwitz, Herbert I. / Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. In: Oncologist. 2008 ; Vol. 13, No. 9. pp. 1021-1029.
@article{8c15769b57ba4c538c89033c32c3dbff,
title = "Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer",
abstract = "Purpose. To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies. Patients and Methods. Prespecified HRQoL endpoints in the phase II (Study 2192) and phase III (Study 2107) studies were time to deterioration in HRQoL, measured by the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Colorectal Cancer Subscale (CCS), Trial Outcome Index (TOI-C), and FACT-C total score. Time to deterioration in HRQoL was evaluated for patients with baseline and postbaseline assessments, using the stratified log-rank test. Results. In the pivotal phase III trial, HRQoL baseline and postbaseline CCS scores were available for 127 patients receiving irinotecan, 5-FU, and leucovorin (LV) (IFL) and 122 patients receiving IFL plus BV. The time to deterioration in HRQoL did not differ significantly between treatment groups as measured by the CCS, TOI-C, or FACT-C total score. In the phase II study, baseline and postbaseline CCS scores were available for 77 and 89 patients receiving 5-FU and LV and 5-FU and LV plus BV, respectively. In that study, the time to deterioration in HRQoL was similar between groups as measured by the CCS and TOI-C scores, but was significantly longer in the 5-FU and LV plus BV arm than in the 5-FU and LV plus placebo arm for the FACT-C total score. Conclusions. When added to 5-FU chemotherapy, BV significantly prolonged overall survival and progression-free survival without compromising HRQoL.",
keywords = "Angiogenesis inhibitors, Bevacizumab, Colorectal cancer, Fluorouracil, Monoclonal antibodies, Quality of life",
author = "Kabbinavar, {Fairooz F.} and Wallace, {Joel F.} and Eric Holmgren and Jing Yi and David Cella and Yost, {Kathleen J} and Hurwitz, {Herbert I.}",
year = "2008",
month = "9",
doi = "10.1634/theoncologist.2008-0003",
language = "English (US)",
volume = "13",
pages = "1021--1029",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "9",

}

TY - JOUR

T1 - Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer

AU - Kabbinavar, Fairooz F.

AU - Wallace, Joel F.

AU - Holmgren, Eric

AU - Yi, Jing

AU - Cella, David

AU - Yost, Kathleen J

AU - Hurwitz, Herbert I.

PY - 2008/9

Y1 - 2008/9

N2 - Purpose. To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies. Patients and Methods. Prespecified HRQoL endpoints in the phase II (Study 2192) and phase III (Study 2107) studies were time to deterioration in HRQoL, measured by the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Colorectal Cancer Subscale (CCS), Trial Outcome Index (TOI-C), and FACT-C total score. Time to deterioration in HRQoL was evaluated for patients with baseline and postbaseline assessments, using the stratified log-rank test. Results. In the pivotal phase III trial, HRQoL baseline and postbaseline CCS scores were available for 127 patients receiving irinotecan, 5-FU, and leucovorin (LV) (IFL) and 122 patients receiving IFL plus BV. The time to deterioration in HRQoL did not differ significantly between treatment groups as measured by the CCS, TOI-C, or FACT-C total score. In the phase II study, baseline and postbaseline CCS scores were available for 77 and 89 patients receiving 5-FU and LV and 5-FU and LV plus BV, respectively. In that study, the time to deterioration in HRQoL was similar between groups as measured by the CCS and TOI-C scores, but was significantly longer in the 5-FU and LV plus BV arm than in the 5-FU and LV plus placebo arm for the FACT-C total score. Conclusions. When added to 5-FU chemotherapy, BV significantly prolonged overall survival and progression-free survival without compromising HRQoL.

AB - Purpose. To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies. Patients and Methods. Prespecified HRQoL endpoints in the phase II (Study 2192) and phase III (Study 2107) studies were time to deterioration in HRQoL, measured by the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Colorectal Cancer Subscale (CCS), Trial Outcome Index (TOI-C), and FACT-C total score. Time to deterioration in HRQoL was evaluated for patients with baseline and postbaseline assessments, using the stratified log-rank test. Results. In the pivotal phase III trial, HRQoL baseline and postbaseline CCS scores were available for 127 patients receiving irinotecan, 5-FU, and leucovorin (LV) (IFL) and 122 patients receiving IFL plus BV. The time to deterioration in HRQoL did not differ significantly between treatment groups as measured by the CCS, TOI-C, or FACT-C total score. In the phase II study, baseline and postbaseline CCS scores were available for 77 and 89 patients receiving 5-FU and LV and 5-FU and LV plus BV, respectively. In that study, the time to deterioration in HRQoL was similar between groups as measured by the CCS and TOI-C scores, but was significantly longer in the 5-FU and LV plus BV arm than in the 5-FU and LV plus placebo arm for the FACT-C total score. Conclusions. When added to 5-FU chemotherapy, BV significantly prolonged overall survival and progression-free survival without compromising HRQoL.

KW - Angiogenesis inhibitors

KW - Bevacizumab

KW - Colorectal cancer

KW - Fluorouracil

KW - Monoclonal antibodies

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=52949151889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949151889&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2008-0003

DO - 10.1634/theoncologist.2008-0003

M3 - Article

C2 - 18776057

AN - SCOPUS:52949151889

VL - 13

SP - 1021

EP - 1029

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 9

ER -